Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Acute myeloid leukemia (AML) with either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) is referred to as core binding factor (CBF) AML. Although categorized as favorable risk, long-term survival for these patients is only ∼50% to 60%. Mutated (mut) or overexpressed KIT, a gene encoding a rec...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood Adv
Glavni autori: Marcucci, Guido, Geyer, Susan, Laumann, Kristina, Zhao, Weiqiang, Bucci, Donna, Uy, Geoffrey L., Blum, William, Eisfeld, Ann-Kathrin, Pardee, Timothy S., Wang, Eunice S., Stock, Wendy, Kolitz, Jonathan E., Kohlschmidt, Jessica, Mrózek, Krzysztof, Bloomfield, Clara D., Stone, Richard M., Larson, Richard A.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2020
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7042984/
https://ncbi.nlm.nih.gov/pubmed/32092139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000492
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items